Ticker: CBPO, Company: China Biologic Products Holdings, Inc., Type: 20-F, Date: 2018-02-28, XBRL Interactive Financials
Original SEC Filing: Click here

---

Webplus: CBPO/20180228/20-F/1/000.htm SEC Original: tv485585_20f.htm

---

---

Webplus: CBPO/20180228/20-F/2_EX-8.1/000.htm SEC Original: tv485585_ex8-1.htm
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC Jurisdiction of Name Incorporation or Organization Taibang Biological Ltd. British Virgin Islands Taibang Holdings (Hong Kong) Limited Hong Kong Health Forward Holdings Limited Hong Kong Tianxinfu (Beijing) Medical Appliance Co., Ltd. PRC Taibang Biotech (Shandong) Co., Ltd. PRC Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd. PRC Shandong Taibang Biological Products Co., Ltd. PRC Qihe Antai

---

---

Webplus: CBPO/20180228/20-F/3_EX-12.1/000.htm SEC Original: tv485585_ex12-1.htm
Certification by the Chief Executive Officer I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 20-F of China Biologic Products Holdings, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,

---

---

Webplus: CBPO/20180228/20-F/4_EX-12.2/000.htm SEC Original: tv485585_ex12-2.htm
Certification by the Chief Financial Officer I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 20-F of China Biologic Products Holdings, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in

---

---

Webplus: CBPO/20180228/20-F/5_EX-13.1/000.htm SEC Original: tv485585_ex13-1.htm
Certification by the Chief Executive Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

---

Webplus: CBPO/20180228/20-F/6_EX-13.2/000.htm SEC Original: tv485585_ex13-2.htm
Certification by the Chief Financial Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. By

---

---

Webplus: CBPO/20180228/20-F/7_EX-15.1/000.htm SEC Original: tv485585_ex15-1.htm
Consent of Independent Registered Public Accounting Firm The Board of Directors Beijing, China February 28, 2018

---

Company Info:

Ticker: CBPO, Company: China Biologic Products Holdings, Inc., Type: 20-F, Date: 2018-02-28, XBRL Interactive FinancialsCIK: 0001369868, Location: F4, SIC: 2836, SIC Desc: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Business Phone & Address:
18TH FL, JIALONG INTERNATIONALBUILDING, 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT
BEIJING 100125